Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Short term Debt (2016 - 2025)

Plus Therapeutics has reported Short term Debt over the past 16 years, most recently at $750000.0 for Q4 2025.

  • Quarterly Short term Debt fell 77.22% to $750000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $750000.0 through Dec 2025, down 77.22% year-over-year, with the annual reading at $750000.0 for FY2025, 77.22% down from the prior year.
  • Short term Debt was $750000.0 for Q4 2025 at Plus Therapeutics, down from $3.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $6.8 million in Q3 2021 and troughed at $750000.0 in Q4 2025.
  • The 5-year median for Short term Debt is $3.3 million (2024), against an average of $3.5 million.
  • Year-over-year, Short term Debt skyrocketed 214.49% in 2023 and then plummeted 77.22% in 2025.
  • A 5-year view of Short term Debt shows it stood at $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022, then skyrocketed by 147.26% to $4.0 million in 2023, then decreased by 17.2% to $3.3 million in 2024, then plummeted by 77.22% to $750000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Short term Debt are $750000.0 (Q4 2025), $3.3 million (Q4 2024), and $3.3 million (Q3 2024).